ArriVent BioPharma Statistics
Total Valuation
AVBP has a market cap or net worth of $1.58 billion. The enterprise value is $1.26 billion.
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AVBP has 46.57 million shares outstanding. The number of shares has increased by 22.48% in one year.
| Current Share Class | 46.57M |
| Shares Outstanding | 46.57M |
| Shares Change (YoY) | +22.48% |
| Shares Change (QoQ) | +4.95% |
| Owned by Insiders (%) | 1.93% |
| Owned by Institutions (%) | 66.52% |
| Float | 29.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 236.46 |
| PB Ratio | 4.75 |
| P/TBV Ratio | 4.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.95, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.95 |
| Quick Ratio | 13.06 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.17% and return on invested capital (ROIC) is -37.20%.
| Return on Equity (ROE) | -55.17% |
| Return on Assets (ROA) | -34.72% |
| Return on Invested Capital (ROIC) | -37.20% |
| Return on Capital Employed (ROCE) | -48.37% |
| Weighted Average Cost of Capital (WACC) | 12.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.89M |
| Employee Count | 77 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.12% in the last 52 weeks. The beta is 1.42, so AVBP's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | +49.12% |
| 50-Day Moving Average | 30.00 |
| 200-Day Moving Average | 23.73 |
| Relative Strength Index (RSI) | 64.60 |
| Average Volume (20 Days) | 765,240 |
Short Selling Information
The latest short interest is 7.85 million, so 16.85% of the outstanding shares have been sold short.
| Short Interest | 7.85M |
| Short Previous Month | 7.71M |
| Short % of Shares Out | 16.85% |
| Short % of Float | 26.35% |
| Short Ratio (days to cover) | 13.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -156.87M |
| Pretax Income | -145.24M |
| Net Income | -145.24M |
| EBITDA | n/a |
| EBIT | -156.87M |
| Earnings Per Share (EPS) | -$3.52 |
Full Income Statement Balance Sheet
The company has $326.38 million in cash and $419,000 in debt, giving a net cash position of $325.96 million or $7.00 per share.
| Cash & Cash Equivalents | 326.38M |
| Total Debt | 419,000 |
| Net Cash | 325.96M |
| Net Cash Per Share | $7.00 |
| Equity (Book Value) | 323.98M |
| Book Value Per Share | 7.15 |
| Working Capital | 323.71M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -134.47M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |